Histone deacetylases (HDACs) are considered to be among the most promising targets in drug development for cancer therapy, and first-generation histone deacetylase inhibitors (HDACi) are currently being tested in phase I/II clinical trials. A wide-ranging knowledge of the role of HDACs in tumorigenesis, and of the action of HDACi, has been achieved. However, several basic aspects are not yet fully understood. Investigating these aspects in the context of what we now understand about HDACi action both in vitro and in vivo will further improve the design of optimized clinical protocols.
Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer / S. Minucci, P.G. Pelicci. - In: NATURE REVIEWS CANCER. - ISSN 1474-175X. - 6:1(2006 Jan), pp. 38-51.
Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer
S. MinucciPrimo
;P.G. PelicciUltimo
2006
Abstract
Histone deacetylases (HDACs) are considered to be among the most promising targets in drug development for cancer therapy, and first-generation histone deacetylase inhibitors (HDACi) are currently being tested in phase I/II clinical trials. A wide-ranging knowledge of the role of HDACs in tumorigenesis, and of the action of HDACi, has been achieved. However, several basic aspects are not yet fully understood. Investigating these aspects in the context of what we now understand about HDACi action both in vitro and in vivo will further improve the design of optimized clinical protocols.File | Dimensione | Formato | |
---|---|---|---|
nrc1779.pdf
accesso aperto
Tipologia:
Pre-print (manoscritto inviato all'editore)
Dimensione
521.99 kB
Formato
Adobe PDF
|
521.99 kB | Adobe PDF | Visualizza/Apri |
Pubblicazioni consigliate
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.